Cell therapy clinical trial documentation must address at least five critical areas to meet regulatory standards, with manufacturing and quality data representing 95% of submission requirements, followed by nonclinical safety studies at 88%. The complexity of these documentation demands reflects the unique nature of advanced therapy medicinal products, which involve living cells, genetic modifications, or tissue engineering approaches.
The Danish Medicines Agency’s newly released Investigator’s Brochure template standardizes how researchers present these essential data elements, ensuring consistency across submissions and reducing the risk of incomplete applications. By providing a structured template aligned with European guidelines, the DKMA enables research teams to systematically address manufacturing quality, nonclinical safety, clinical pharmacology, human experience, and risk mitigation strategies. This standardization approach is expected to significantly improve submission efficiency while strengthening the evidence base for cell therapy development.
Was this article helpful?
